AnaptysBio (ANAB) Earnings Call Presentation

Rosnilimab: Updated Phase 2b Data in RA June 3, 2025 Safe harbor statement This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company's clinical trials, including rosnilimab's Phase 2b clinical trial in rheumatoid arthritis at Week 38 and top-line data for rosnilimab's Phase 2 clinical t ...